Statement issued by the company (Announcement)<\/p>\n
Fortrea<\/u><\/a> <\/strong>(Nasdaq: FTRE) (the \u201cCompany\u201d), a leading global contract research organization<\/strong> (CRO<\/strong>), today announced its comprehensive and integrated solution to improve the diversity and inclusion<\/strong> (D&I) of participants in clinical trials. Fortrea\u2019s D&I solution is designed to expand patient access to participate in clinical trials and address the U.S. Food and Drug Administration (FDA) requirements, under The Food and Drug Omnibus Reform Act, to increase enrollment of underrepresented populations in clinical trials.<\/p>\n Fortrea\u2019s comprehensive process integrates five components of diversity action planning and execution:<\/p>\n “Clinical research that reflects a representative population provides better insight into how a potential treatment will work in a real-world setting,\u201d said John Doyle<\/strong>, DrPH, president Fortrea Consulting. “Recent regulatory requirements codify progress over the last few years in biopharma\u2019s approach to improving the inclusion of diverse populations in their development programs. Fortrea\u2019s solution brings deep, real-world data expertise to design D&I plans that are effective and realistic, along with more than 30 years of experience across more than 20 therapeutic areas in trial execution. We also bring a steadfast commitment to D&I, not just in clinical trials but across our entire company as we pursue our purpose of bringing life-changing treatments to patients faster.”<\/p>\n Fortrea\u2019s D&I solution incorporates a series of proprietary tools<\/strong>, including epidemiological and feasibility assessments that leverage an exclusive combination of large data sets. The solution also integrates inputs from patient groups to create insights into protocol tolerance and study conduct support requirements in different patient populations across multiple therapy areas and geographies. These insights inform global and local patient recruitment and retention plans to reach under-represented patient populations and address barriers to participation in clinical trials.<\/p>\n \u201cEnsuring the inclusion of diverse patient populations in clinical trials must go beyond a plan, it takes insight and action,\u201d said Mark Morais<\/strong>, chief operating officer, Fortrea. \u201cBecause of our comprehensive Voice of Patient program and our collaboration with diverse investigator sites and site networks, we have a deep understanding of what it takes to be successful in reaching populations that have traditionally been under-represented in clinical trials. At Fortrea, we are informed by real-world data, enabled by innovative technologies, and driven by our passion to deliver new therapies for all patients.\u201d<\/p>\n Please visit\u00a0Diversity and Inclusion in Clinical Trials<\/a> on Fortrea.com<\/a> for more information.<\/p>\n Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development and patient access solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life-changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology, consulting services, differentiated technology enabled trial solutions and post-approval services.<\/p>\n Fortrea\u2019s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally.<\/p>\n Learn more about how Fortrea is becoming a transformative force from pipeline to patient at\u00a0Fortrea.com<\/a>\u00a0and follow us on\u00a0LinkedIn<\/a>\u00a0and\u00a0X<\/a>\u00a0(formerly Twitter) @Fortrea.<\/p>\n AGENCIA EFE S.A.U. shall not be liable for any information contained in this message and assumes no responsibility towards third parties in relation to its contents, being expressly exempt from any liability that the author may have in relation to the information in question.<\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":" Statement issued by the company (Announcement) Leverages real-world data, patient insights and a systematic process to design,\u00a0operationalize and measure the effectiveness of diversity action plans in clinical trials Fortrea (Nasdaq: […]<\/p>\n","protected":false},"author":198164071,"featured_media":48434,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[125518],"tags":[],"class_list":["post-113942","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire-en"],"acf":[],"yoast_head":"\n\n
About Fortrea<\/h2>\n
Fortrea Contacts:<\/strong>\r\nFortrea Media: Galen Wilson \u2013 703-298-0802, media@fortrea.com<\/u><\/a>\r\nFortrea Media: Kate Dillon \u2013 646-818-9115, kdillon@prosek.com<\/u><\/a><\/pre>\n